Clesrovimab

Last updated

Clesrovimab
Monoclonal antibody
Type Whole antibody
Source Human
Target Respiratory syncytial virus F protein
Clinical data
Trade names Enflonsia
Other namesMK-1654, clesrovimab-cfor
AHFS/Drugs.com Enflonsia
License data
Routes of
administration
Intramuscular
Drug class Antiviral
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
Formula C6526H10118N1732O2039S40
Molar mass 146747.22 g·mol−1

Clesrovimab, sold under the brand name Enflonsia, is a fully human immunoglobulin G1 kappa monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. [1] It is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor. [1] It was developed by Merck, [2] and was approved for medical use in the United States in June 2025. [3]

Contents

Medical uses

Clesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. [1]

Society and culture

Clesrovimab was approved for medical use in the United States in June 2025. [2] [4]

Names

Clesrovimab is the international nonproprietary name. [5]

Clesrovimab is sold under the brand name Enflonsia. [1]

References

  1. 1 2 3 4 5 "Enflonsia- clesrovimab injection, solution". DailyMed. 20 June 2025. Retrieved 6 July 2025.
  2. 1 2 "U.S. FDA Approves Merck's Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season" (Press release). Merck. 9 June 2025. Archived from the original on 14 June 2025. Retrieved 14 June 2025 via Business Wire.
  3. "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 9 June 2025. Archived from the original on 3 March 2025. Retrieved 14 June 2025.
  4. "Clesrovimab Receives FDA Approval for RSV Lower Respiratory Tract Prevention in Infants". Archived from the original on 9 June 2025. Retrieved 12 June 2025.
  5. World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl: 10665/363551 .

Further reading